epithalon uses 10mg | Research Peptide Epitalon - Polar Peptides

A recent phase 2 trial investigated the triple biased GLP-1/GIP/GCC receptors agonist retatrutide (LY3437943) in 338 patients with a mean age of 48 years and BMI of 37.3 kg/m 2 without diabetes (prediabetes in 36% participants) showing BW and WC reduction ranging from 8.7% to 24.2% and 6.5 cm to 19.6 cm in the 1 mg and 12 mg dose groups, respectively, at 48 weeks 41

Systemic bioavailability is higher with subcutaneous injection (roughly 90% vs

Purity standard: 99% based on available third-party documentation

Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026

it is not approved for human or veterinary use, and nothing below describes or recommends any form of administration to people

This pilot study evaluated BPC-157 in patients with interstitial cystitis, making it one of the few human trials